ResearcherNankai UniversityActive in the last 2 years

Zhen Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6058-0217; OpenAlex author ID A5115602239. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 2 papers

Papers 2

EPYC functions as a novel prognostic biomarker for pancreatic cancer. Co-author DOI 10.1038/s41598-024-51478-w ↗
Erianin inhibits the progression of pancreatic cancer by directly targeting AKT and ASK1. Co-author DOI 10.1186/s12935-024-03533-9 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jie Hao · 2 shared papers, 2024 · strength 0.44
- Paper EPYC functions as a novel prognostic biomarker for pancreatic cancer. DOI 10.1038/s41598-024-51478-w ↗
- Paper Erianin inhibits the progression of pancreatic cancer by directly targeting AKT and ASK1. DOI 10.1186/s12935-024-03533-9 ↗
Ming Gao · 1 shared paper, 2024 · strength 0.24
- Paper EPYC functions as a novel prognostic biomarker for pancreatic cancer. DOI 10.1038/s41598-024-51478-w ↗
Huaqing Wang · 1 shared paper, 2024 · strength 0.20
- Paper Erianin inhibits the progression of pancreatic cancer by directly targeting AKT and ASK1. DOI 10.1186/s12935-024-03533-9 ↗
Ruxue Liu · 1 shared paper, 2024 · strength 0.20
- Paper Erianin inhibits the progression of pancreatic cancer by directly targeting AKT and ASK1. DOI 10.1186/s12935-024-03533-9 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.